

The *CRC* research network was involved in multiple national cooperations and scientific networks within Germany. In addition, several *CRC* groups have long-standing and close international cooperations with cardiovascular, immunological, molecular and cell biological research groups within Europe and in North America.

For the final year of funding (2013), part of these international cooperations, and of interactions with other research networks in the context of *CRC*, is listed below:

A1 GOTTHARDT

Bezzina C. (Univ. of Amsterdam, Netherlands): CAR human genetics

Granzier H. (Univ. of Arizona, Tucson, AZ, USA): biomechanics, immunoelectron microscopy

MacRae C. (Massachusetts General Hospital, Boston, MA, USA): genetics of cardiomyopathy

A2 WESTERMANN - SCHULTHEISS

Heymans S. (Univ. of Maastricht, Netherlands). matrix remodeling

Diez J. (Hospital Ramón y Cajal, Madrid, Spain): cardiac collagen

Paulus W. (University Medical Center, Amsterdam, Netherlands): diastolic heart failure

A3 RAUCH

Badimon J. (Mount Sinai School of Medicine, New York, NY, USA): tissue factor

Bogdanov V. (Univ. of Cincinnati, OH, USA) alternative splicing in the cardiovascular system

Fuster V. (Mount Sinai School of Medicine, New York, NY, USA): tissue factor

Knapp S. (Univ. of Oxford, UK): cdc2-like kinase inhibitors

Mackman N. (Univ. of North Carolina at Chapel Hill, NC, USA): tissue factor and PARs

Meijer L. (CNRS, Roscoff, France): pharmaceutical inhibitors of DYRKs in endothelial cells

B5 LANG – KANDOLF

Binh V. & Song le H. (Dept. of Infectious Diseases, Vietnam Military Medical Univ., Hanoi, Vietnam)

Brosens J. (Imperial College London, London, UK): Regulation of ion transport by SGK1

Grassi G. (University of Trieste, Italy)

Knowlton K. (University of California, San Diego, CA, USA)

Locarnini S. (Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia)

McManus B. (University of British Columbia, Vancouver, Canada)

Schroen B. (CARIM, Univ. of Maastricht, Netherlands)

Torresi J. (Dept. of Infectious Diseases, Univ. of Melbourne, Australia)

B7 SKURK – SCHEIBENBOGEN

Eriksson U. (Inst. of Physiology and Center for Integrative Human Physiology, Zurich, Switzerland)

Liu P. (Toronto General Hospital, Toronto, ON, Canada)

Walsh L. (Whitaker Cardiovascular Institute, Boston Univ. Medical College, Boston, MA, USA)

B8 BORST - GAWAZ

Alessi D. (MRC Protein Phosphorylation Unit, University of Dundee, UK)

C5 POLLER - SCHEIBENBOGEN

Hajjar R. (Mount Sinai School of Medicine, New York, NY, USA): gene and RNAi therapy

Liu P. (Toronto General Hospital, Toronto, ON, Canada): innate immunity, chemotaxis

Heymans S.m Schroen B. (CARIM, Univ. of Maastricht, Netherlands): miRs, long noncoding RNAs

Eriksson U. (Univ. of Zurich Medical School, Zurich, Switzerland): Autoimmune heart disease

Z1 SCHULTHEISS – KÜHL - ESCHER

Krueger G. & Ablashi D. (HHV6 Foundation, Santa Barbara, CA, USA)

Z2 HOFFMANN – FELIX

Research Network “*Community Medicine*” e.g. SHIP-0, SHIP-1, SHIP-2, SHIP-Trend

Epidemiologic Planning Committee of the *German National Cohort*

German Centre for Cardiovascular Research (Deutsche Zentrum für Herz-Kreislauf-Forschung)

Greifswald Approach to Individualized Medicine (GANI_MED)

Z4 KLINGEL – NÜRNBERG

Backer J. (New York, USA): Regulation and Role of PI3Ks

Hirsch E. (Torino, Italy): PI3K-k.o. mouse strains

To T. (Hong Kong, China): Role of PI3Ks in brain tumors

Williams R. (Cambridge, UK): Structural analysis of PI3Ks

Wymann M. (Basel, Switzerland): Role of PI3K in mast cells